Pulmonary Sarcoidosis That Developed During the Treatment of a Patient With Crohn Disease by Using Infliximab
Annals of Coloproctology
;
: 74-77, 2017.
Article
in English
| WPRIM
| ID: wpr-33735
ABSTRACT
For inflammatory bowel disease (IBD), antitumor necrosis factor treatment offers a new direction for both patients and medical doctors. This treatment has dramatically improved the quality of life for patients with ulcerative colitis and Crohn disease (CD). However, with increasing usage and longer follow-up periods, a wider range of possible adverse effects may be encountered. We report an unusual case of pulmonary sarcoidosis developed during the treatment of a patient with CD by using infliximab. A 30-year-old male who had been treated for CD with infliximab for 18 months was admitted due to abnormal opacities on chest radiography. Chest computed tomography displayed clustered small nodules in both lobes and enlarged multiple lymph nodes. The patient was diagnosed with sarcoidosis from the results of a biopsy of the subcarinal lymph node. Lung lesions were improved five months after infliximab was stopped.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quality of Life
/
Sarcoidosis
/
Thorax
/
Biopsy
/
Radiography
/
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
Crohn Disease
/
Follow-Up Studies
/
Tumor Necrosis Factor-alpha
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Annals of Coloproctology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS